Clinical Research Directory

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

CAMPR-II Trial: A multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a saline-hydrated allogeneic dual-layer amniotic membrane product or a synthetic, resorbable polymeric wound matrix to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs

Borate-based Bioactive Glass Fiber Matrix (BBGFM) in the Treatment of Venus Leg Ulcers (VLU)

The goal of this clinical trial is to learn if Borate-based Bioactive Glass Fiber Matrix (BBGFM) can help heal Venous Leg Ulcers (VLU) that have not closed with standard treatment. The main question it aims to answer is: 1\. Does BBGFM help Venus Leg Ulcers heal completely in 12 weeks? Researchers will compare BBGFM plus Standard of Care (SOC) to SOC alone to see if BBGFM works to heal wounds. Participants will: * Have BBGFM applied to their wound (if assigned to the BBGFM group) for up to 12 applications * Visit the clinic each week for wound checks and tests Other study purposes include looking at: * The time it takes for the wound to heal * Changes in wound size over time * The durability of wound healing after closure * The use of healthcare resources related to wound care * Any adverse events (side effects) or reactions related to the treatment * Changes in pain levels * Changes in quality of life